A Phase 3 interventional study of placebo for risankizumab and risankizumab IV in Crohn's Disease, sponsored by AbbVie. Completed at 475 sites in 44 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-06.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing risankizumab in Crohn Disease — 7 open to participants now, 10 under way, 6 of them phase 3. risankizumab · Crohn Disease.
Among the 16 studies testing risankizumab in Crohn Disease, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 3rd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →7 of the 16 studies testing risankizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Yuki Horio · Sites in Japan
Ages 15+
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
Shaare Zedek Medical Center · Sites in Israel
Ages 6–18
AbbVie · Sites in United States, Austria, Belgium and 30 more countries
Ages 18–75
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
This study's enrollment of 931 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 275 across the 16 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Crohn Disease by AbbVie: 6 open now, 14 under way, 6 of them phase 3. Of 38 finished, 28 (74%) have results posted.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2017, is one of 16 in phase 3, and was the 28th registered.
AbbVie’s Crohn Disease studies by the year they started, since 2007.
1 of the studies testing risankizumab in Crohn Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing risankizumab in Crohn Disease, from their registry updates:
Among AbbVie’s 55 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
Drug: risankizumab IV
Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
Drug: placebo for risankizumab
Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
Drug: risankizumab IV
Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
Drug: risankizumab SC
Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
Drug: risankizumab SC
Placebo for risankizumab administered by intravenous infusion
Risankizumab administered by intravenous infusion
Also known as: ABBV-066 BI 655066, SKYRIZI
Risankizumab administered by subcutaneous (SC) injection
Also known as: ABBV-066 BI 655066, SKYRIZI
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.
Time frame: Week 12
US Specific: Percentage of Participants With Endoscopic Response
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Time frame: Week 12
Global Outside of US: Percentage of Participants With Clinical Remission
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Time frame: Week 12
Global Outside of US: Percentage of Participants With Endoscopic Response
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Time frame: Week 12
US Specific: Percentage of Participants With Clinical Remission
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Time frame: Week 12
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Time frame: Week 4
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Time frame: Week 12
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
Time frame: Week 12
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.
Time frame: Week 4
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline. Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).
Time frame: Week 12
US Specific: Percentage of Participants With Stool Frequency (SF) Remission
Stool Frequency (SF) remission is defined as an average daily SF \<= 2.8 and not worse than baseline.
Time frame: Week 12
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission
The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \<= 1 and not worse than baseline.
Time frame: Week 12
US Specific: Percentage of Participants With Endoscopic Remission
Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable
Time frame: Week 12
US Specific: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Time frame: Week 4
US Specific: Percentage of Participants With Ulcer-Free Endoscopy
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline
Time frame: Week 12
US Specific: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Time frame: Week 12
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at
Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
Time frame: Week 12
US Specific: Percentage of Participants With CD-Related Hospitalization
Participants with at least one admission to the hospital due to Crohn's Disease.
Time frame: Week 12
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
Time frame: Week 12
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.
Time frame: Week 12
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Time frame: Week 4
Global Outside of US: Percentage of Participants With Clinical Remission
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
Time frame: Week 4
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
Time frame: Week 12
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
Time frame: Week 12
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
Time frame: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response
Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).
Time frame: Week 12
Global Outside of US: Percentage of Participants With Endoscopic Remission
Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable
Time frame: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Time frame: Week 4
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline
Time frame: Week 12
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
Time frame: Week 12
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline
Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
Time frame: Week 12
Global Outside of US: Percentage of Participants With CD-Related Hospitalization
Participants with at least one admission to the hospital due to Crohn's Disease.
Time frame: Week 12
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
Time frame: Week 12
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment
WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \[OWI\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Week 12
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score
The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
Time frame: Week 12
Subjects were randomized to receive 600mg risankizumab, 1200mg risankizumab or placebo during the double-blind, placebo-controlled Period 1. At Week 12, subjects who do not achieve clinical response were randomized into Period 2 to receive 180mg risankizumab, 360mg risankizumab or 1200mg risankizumab. Subjects who received placebo received 1200mg.
| Milestone | Risankizumab 600mg (Induction Period 1) | Risankizumab 1200mg (Induction Period 1) | Placebo (Induction Period 1) | Risankizumab 180mg (Induction Period 2) | Risankizumab 360mg (Induction Period 2) | Risankizumab 1200mg (Induction Period 2) | Placebo/Risankizumab IV (Induction Period 2) |
|---|---|---|---|---|---|---|---|
| Started | 373 | 372 | 186 | 0 | 0 | 0 | 0 |
| Completed | 365 | 366 | 163 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 6 | 23 | 0 | 0 | 0 | 0 |
| Milestone | Risankizumab 600mg (Induction Period 1) | Risankizumab 1200mg (Induction Period 1) | Placebo (Induction Period 1) | Risankizumab 180mg (Induction Period 2) | Risankizumab 360mg (Induction Period 2) | Risankizumab 1200mg (Induction Period 2) | Placebo/Risankizumab IV (Induction Period 2) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 67 | 68 | 67 | 76 |
| Completed | 0 | 0 | 0 | 62 | 65 | 64 | 74 |
| Not completed | 0 | 0 | 0 | 5 | 3 | 3 | 2 |
The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission | 24.6 (18.2 to 31.0) | 45.2 (39.9 to 50.5) | 41.6 (36.3 to 46.8) |
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Endoscopic Response | 12.0 (7.2 to 16.8) | 40.3 (35.0 to 45.6) | 32.1 (27.1 to 37.1) |
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Clinical Remission | 21.7 (15.6 to 27.8) | 43.5 (38.2 to 48.8) | 41.0 (35.8 to 46.2) |
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Endoscopic Response | 12.0 (7.2 to 16.8) | 40.3 (35.0 to 45.6) | 32.1 (27.1 to 37.1) |
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Clinical Remission | 21.7 (15.6 to 27.8) | 43.5 (38.2 to 48.8) | 41.0 (35.8 to 46.2) |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response | 25.2 (18.7 to 31.6) | 40.8 (35.5 to 46.0) | 37.2 (32.0 to 42.3) |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response | 36.7 (29.6 to 43.9) | 59.7 (54.5 to 65.0) | 64.9 (59.8 to 70.0) |
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue | 6.0 (4.4 to 7.7) | 11.2 (10.1 to 12.4) | 10.1 (9.0 to 11.3) |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission | 10.3 (5.8 to 14.8) | 18.4 (14.3 to 22.6) | 18.9 (14.7 to 23.0) |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline. Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response | 5.7 (2.3 to 9.2) | 30.0 (25.1 to 34.9) | 23.0 (18.5 to 27.5) |
Stool Frequency (SF) remission is defined as an average daily SF \<= 2.8 and not worse than baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Stool Frequency (SF) Remission | 29.8 (23.1 to 36.6) | 54.2 (48.8 to 59.5) | 54.0 (48.7 to 59.3) |
The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \<= 1 and not worse than baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Abdominal Pain (AP) Remission | 38.5 (31.2 to 45.7) | 59.6 (54.3 to 64.8) | 58.1 (52.9 to 63.4) |
Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Endoscopic Remission | 9.1 (4.9 to 13.4) | 24.2 (19.6 to 28.7) | 23.9 (19.4 to 28.5) |
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Enhanced Clinical Response | 31.0 (24.1 to 37.9) | 46.0 (40.7 to 51.3) | 43.4 (38.1 to 48.6) |
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Ulcer-Free Endoscopy | 7.6 (3.6 to 11.5) | 21.0 (16.6 to 25.4) | 16.4 (12.4 to 20.3) |
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Enhanced Clinical Response | 41.9 (34.6 to 49.3) | 62.8 (57.6 to 68.0) | 64.3 (59.2 to 69.4) |
Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at | 20.5 (10.5 to 30.4) | 38.1 (30.0 to 46.1) | 43.7 (35.9 to 51.4) |
Participants with at least one admission to the hospital due to Crohn's Disease.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants With CD-Related Hospitalization | 12.0 (7.2 to 16.8) | 3.3 (1.4 to 5.2) | 1.8 (0.4 to 3.2) |
Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline | 22.2 (0.0 to 49.4) | 27.8 (7.1 to 48.5) | 29.2 (11.0 to 47.4) |
The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission | 24.6 (18.2 to 31.0) | 45.2 (39.9 to 50.5) | 41.6 (36.3 to 46.8) |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response | 25.2 (18.7 to 31.6) | 40.8 (35.5 to 46.0) | 37.2 (32.0 to 42.3) |
Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Clinical Remission | 9.1 (4.9 to 13.4) | 21.0 (16.6 to 25.3) | 21.2 (16.9 to 25.6) |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response | 36.7 (29.6 to 43.9) | 59.7 (54.5 to 65.0) | 64.9 (59.8 to 70.0) |
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.
| units on a scale | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue | 6.0 (4.4 to 7.7) | 11.2 (10.1 to 12.4) | 10.1 (9.0 to 11.3) |
The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.
| units on a scale | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score | 23.6 (18.2 to 28.9) | 44.3 (40.6 to 48.0) | 43.0 (39.4 to 46.6) |
Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response | 8.0 (4.0 to 12.0) | 30.9 (25.9 to 35.8) | 23.2 (18.7 to 27.8) |
Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Endoscopic Remission | 9.1 (4.9 to 13.4) | 24.2 (19.6 to 28.7) | 23.9 (19.4 to 28.5) |
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Enhanced Clinical Response | 31.0 (24.1 to 37.9) | 46.0 (40.7 to 51.3) | 43.4 (38.1 to 48.6) |
Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy | 7.6 (3.6 to 11.5) | 21.0 (16.6 to 25.4) | 16.4 (12.4 to 20.3) |
Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Enhanced Clinical Response | 41.9 (34.6 to 49.3) | 62.8 (57.6 to 68.0) | 64.3 (59.2 to 69.4) |
Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline | 20.5 (10.5 to 30.4) | 38.1 (30.0 to 46.1) | 43.7 (35.9 to 51.4) |
Participants with at least one admission to the hospital due to Crohn's Disease.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants With CD-Related Hospitalization | 12.0 (7.2 to 16.8) | 3.3 (1.4 to 5.2) | 1.8 (0.4 to 3.2) |
Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
| percentage of participants | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline | 22.2 (0.0 to 49.4) | 27.8 (7.1 to 48.5) | 29.2 (11.0 to 47.4) |
WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \[OWI\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
| units on a scale | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment | -8.344 ± 3.5640 | -17.930 ± 2.3446 | -20.485 ± 2.3112 |
The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
| units on a scale | Placebo (Period 1) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) |
|---|---|---|---|
| Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score | 5.482 ± 0.5985 | 8.394 ± 0.4107 | 8.756 ± 0.4071 |
Collected over Treatment-emergent AEs (TEAEs) are from first dose of study drug until 140 days following last dose of study drug. The median duration of treatment for Period 1 with study drug for placebo and Risankizumab was 91.5 and 91 days respectively. For Period 2, the median duration of treatment with study drug for Risankizumab was 141 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1 Placebo IV | 2/186 (1.1%) | 28/186 (15.1%) | 35/186 (18.8%) |
| Period 1 Risankizumab 600mg IV | 0/373 (0%) | 27/373 (7.2%) | 67/373 (18%) |
| Period 1 Risankizumab 1200mg IV | 0/372 (0%) | 14/372 (3.8%) | 58/372 (15.6%) |
| Period 1 Risankizumab Total | 0/745 (0%) | 41/745 (5.5%) | 125/745 (16.8%) |
| Period 2 Risankizumab 180mg SC | 0/67 (0%) | 3/67 (4.5%) | 4/67 (6%) |
| Period 2 Risankizumab 360mg SC | 0/68 (0%) | 3/68 (4.4%) | 7/68 (10.3%) |
| Period 2 Risankizumab 1200mg IV | 0/67 (0%) | 4/67 (6%) | 4/67 (6%) |
| Period 2 Placebo/Risankizumab 1200mg IV | 0/76 (0%) | 4/76 (5.3%) | 12/76 (15.8%) |
| Period 2 Risankizumab Total | 0/278 (0%) | 14/278 (5%) | 27/278 (9.7%) |
| Event | Period 1 Placebo IV | Period 1 Risankizumab 600mg IV | Period 1 Risankizumab 1200mg IV | Period 1 Risankizumab Total | Period 2 Risankizumab 180mg SC | Period 2 Risankizumab 360mg SC | Period 2 Risankizumab 1200mg IV | Period 2 Placebo/Risankizumab 1200mg IV | Period 2 Risankizumab Total |
|---|---|---|---|---|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 15/186 | 5/373 | 2/372 | 7/745 | 1/67 | 0/68 | 0/67 | 0/76 | 1/278 |
| ABDOMINAL HERNIAGastrointestinal disorders | 0/186 | 0/373 | 0/372 | 0/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| GASTROINTESTINAL NECROSISGastrointestinal disorders | 1/186 | 0/373 | 0/372 | 0/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| INTESTINAL ISCHAEMIAGastrointestinal disorders | 0/186 | 0/373 | 0/372 | 0/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 2/186 | 1/373 | 0/372 | 1/745 | 1/67 | 1/68 | 0/67 | 1/76 | 3/278 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/186 | 1/373 | 1/372 | 2/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| VOMITINGGastrointestinal disorders | 1/186 | 1/373 | 0/372 | 1/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| CHOLECYSTITIS ACUTEHepatobiliary disorders | 0/186 | 0/373 | 0/372 | 0/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| OBSESSIVE-COMPULSIVE DISORDERPsychiatric disorders | 0/186 | 0/373 | 0/372 | 0/745 | 0/67 | 0/68 | 1/67 | 0/76 | 1/278 |
| CALCULUS URINARYRenal and urinary disorders | 0/186 | 0/373 | 0/372 | 0/745 | 1/67 | 0/68 | 0/67 | 0/76 | 1/278 |
| Event | Period 1 Placebo IV | Period 1 Risankizumab 600mg IV | Period 1 Risankizumab 1200mg IV | Period 1 Risankizumab Total | Period 2 Risankizumab 180mg SC | Period 2 Risankizumab 360mg SC | Period 2 Risankizumab 1200mg IV | Period 2 Placebo/Risankizumab 1200mg IV | Period 2 Risankizumab Total |
|---|---|---|---|---|---|---|---|---|---|
| HEADACHENervous system disorders | 8/186 | 24/373 | 20/372 | 44/745 | 1/67 | 3/68 | 2/67 | 5/76 | 11/278 |
| NASOPHARYNGITISInfections and infestations | 5/186 | 22/373 | 22/372 | 44/745 | 1/67 | 1/68 | 1/67 | 2/76 | 5/278 |
| CROHN'S DISEASEGastrointestinal disorders | 10/186 | 5/373 | 4/372 | 9/745 | 2/67 | 1/68 | 0/67 | 0/76 | 3/278 |
| NAUSEAGastrointestinal disorders | 10/186 | 16/373 | 13/372 | 29/745 | 1/67 | 0/68 | 0/67 | 3/76 | 4/278 |
| ANAEMIABlood and lymphatic system disorders | 5/186 | 11/373 | 9/372 | 20/745 | 0/67 | 2/68 | 1/67 | 4/76 | 7/278 |
Consists of all subjects who received at least 1 dose of study medication.
| Age, Categorical(Participants) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) | Placebo (Period 1) | Total |
|---|---|---|---|---|
| <=18 years | 3 | 4 | 2 | 9 |
| Between 18 and 65 years | 355 | 350 | 175 | 880 |
| >=65 years | 15 | 18 | 9 | 42 |
| Age, Continuous(years) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) | Placebo (Period 1) | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 13.22 | 37.6 ± 13.55 | 37.5 ± 13.51 | 37.9 ± 13.40 |
| Sex: Female, Male(Participants) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) | Placebo (Period 1) | Total |
|---|---|---|---|---|
| Female | 168 | 173 | 93 | 434 |
| Male | 205 | 199 | 93 | 497 |
| Ethnicity (NIH/OMB)(Participants) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) | Placebo (Period 1) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 18 | 10 | 41 |
| Not Hispanic or Latino | 360 | 354 | 176 | 890 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Risankizumab 600mg (Period 1) | Risankizumab 1200mg (Period 1) | Placebo (Period 1) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 68 | 75 | 32 | 175 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 2 |
| Black or African American | 10 | 13 | 9 | 32 |
| White | 291 | 279 | 144 | 714 |
| More than one race | 4 | 4 | 0 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 475 sites across 44 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from May 2017 to primary completion in Nov 2020, 41 months.
Results were first posted in Jul 2022, 1 year 7 months after primary completion. A results delay was requested in Jul 2021.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 41 months is below that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab